Inspire Medical Systems, Inc. (FRA:2DR)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.51B -37.5% |
| Revenue (ttm) | 786.67M +4.3% |
| Net Income | 118.20M +154.2% |
| EPS | 4.03 +164.4% |
| Shares Out | n/a |
| PE Ratio | 12.80 |
| Forward PE | 44.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 52.00 |
| Previous Close | 51.50 |
| Day's Range | 51.50 - 52.00 |
| 52-Week Range | 33.60 - 121.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open ai... [Read more]
Financial Performance
In 2025, Inspire Medical Systems's revenue was $911.98 million, an increase of 13.60% compared to the previous year's $802.80 million. Earnings were $145.42 million, an increase of 171.77%.
Financial numbers in USD Financial StatementsNews
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minima...
Inspire Medical price target raised to $60 from $54 at JPMorgan
JPMorgan raised the firm’s price target on Inspire Medical (INSP) to $60 from $54 and keeps a Neutral rating on the shares.
Inspire Medical price target raised to $65 from $55 at Mizuho
Mizuho raised the firm’s price target on Inspire Medical (INSP) to $65 from $55 and keeps an Outperform rating on the shares.
Inspire Medical price target raised to $54 from $40 at Evercore ISI
Evercore ISI raised the firm’s price target on Inspire Medical (INSP) to $54 from $40 and keeps an In Line rating on the shares.
Inspire Medical price target raised to $45 from $39 at BofA
BofA analyst Travis Steed raised the firm’s price target on Inspire Medical (INSP) to $45 from $39 and keeps an Underperform rating on the shares. The firm, which updated its…
Inspire Medical price target raised to $62 from $54 at Truist
Truist raised the firm’s price target on Inspire Medical (INSP) to $62 from $54 and keeps a Hold rating on the shares. Inspire Medical delivered a better-than-feared quarter with a…
Inspire Medical price target raised to $75 from $65 at Stifel
Stifel raised the firm’s price target on Inspire Medical (INSP) to $75 from $65 and keeps a Buy rating on the shares.
Oppenheimer tactically upgrades Inspire Medical despite noisy fundamentals
As previously reported, Oppenheimer analyst Suraj Kalia upgraded Inspire Medical (INSP) to Outperform from Perform with an $85 price target The firm notes the company’s Q2 revenues of $201M slightly…
Inspire Medical upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Inspire Medical (INSP) to Outperform from Perform with an $85 price target
Inspire Medical price target raised to $60 from $55 at Piper Sandler
Piper Sandler raised the firm’s price target on Inspire Medical (INSP) to $60 from $55 and keeps a Neutral rating on the shares following quarterly results. The firm notes management…
Inspire Medical price target raised to $59 from $54 at Baird
Baird raised the firm’s price target on Inspire Medical (INSP) to $59 from $54 and keeps a Neutral rating on the shares. The firm updated its model following beat and…
Inspire Medical Systems Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue decline 7.6% to $200.6M due to coding and reimbursement disruptions, but profitability and cash flow exceeded expectations. Project Horizon was launched to drive future growth, and the 2026 outlook was raised, with sequential improvement expected in the second half.
Inspire Medical Systems Earnings release: Q2 2026
Inspire Medical Systems released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Inspire Medical Systems Quarterly report: Q2 2026
Inspire Medical Systems has published its Q2 2026 quarterly earnings report on August 3, 2026.
Inspire Medical Systems Slides: Q2 2026
Inspire Medical Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
Generated second quarter revenue of $200.6 million Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 Second quarter operating cash flow of $23.2 million Announced strategic growth pla...
Inspire Medical assumed with Sell from Neutral at UBS
UBS analyst Patrick Wood downgraded Inspire Medical (INSP) to Sell from Neutral with a price target of $39, down from $67, after assuming coverage of the name. After nearly two…
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructiv...
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructiv...
Inspire Medical price target raised to $54 from $50 at Truist
Truist raised the firm’s price target on Inspire Medical (INSP) to $54 from $50 and keeps a Hold rating on the shares as part of a broader research note previewing…
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed.
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, Aug...
Inspire Medical initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Inspire Medical (INSP) with a Buy rating and $62 price target The neurostimulation market is an attractive growth opportunity where small-to-mid cap players like ...
Inspire Medical Systems Transcript: Wells Fargo 2026 MedTech Innovation Spotlight
Clear coding and reimbursement pathways are now in place, with Inspire V showing improved clinical outcomes and strong patient adherence. New data links therapy to reduced cardiovascular risk, while ongoing innovation and market education support future growth.